This is a standard retention tool for a biotech approaching catalysts, no departure or appointment signal. Monitor upcoming catalyst readouts for the real stock-moving events; the retention program itself has no trading implications.
KPTI drugs
KPTI drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 20 $7.47entry
- T+1 · 4mo ago +5.29%α +4.45% · $7.87
- T+5 · 4mo ago −0.80%α −0.38% · $7.41
- T+20 · 3mo ago −75.77%α −79.89% · $1.81
- T+60 · 5w ago −94.28%α −99.12% · $0.4274
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Karyopharm Therapeutics implemented a 2026 Leadership Cash Retention Program providing lump-sum cash awards totaling $3.715 million to its CEO, CFO, and two other named executive officers. The program replaces the 2026 Annual Bonus Plan and is designed to retain key personnel through an upcoming catalyst period, with awards subject to clawback if employment terminates before 12 months (or 30 days post-change-of-control). This is a routine compensatory arrangement with no departure or appointment of officers, neutral for the stock.
Key Facts
- CEO Richard Paulson receives $1,725,000 retention award
- CFO Lori Macomber receives $625,000 retention award
- Total retention awards to named executive officers: $3,715,000
- Program replaces previously guaranteed 2026 Annual Bonus Plan amounts
- Awards subject to clawback if employment ends before 12 months (or 30 days post-change-of-control) for reasons other than without-cause termination, good reason resignation, death, or permanent disability
- Retention awards reduce amounts payable under existing severance arrangements
Financial Impact
$3.715 million in aggregate cash retention awards to four named executive officers
Risk Factors
- Retention awards may not prevent key departure if catalyst results are negative
- Cash outlay of $3.715M reduces cash runway modestly
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-307964 |
| Document: 0001193125-26-307964-index-headers.html | 0001193125-26-307964 |
| Document: 0001193125-26-307964-index.html | 0001193125-26-307964 |
| Document: 0001193125-26-307964.txt | 0001193125-26-307964 |
Track record
30 reports on KPTI
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +97.24% at T+60 after the Aug 13, 2026 report. 13 of 14 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $0.0102 Now $0.0290 +184.31% settles Feb 12
- Nov 13, 20263d ago NT 10-Q Bearish 7/10 Entry $0.0102 Now $0.0290 −184.31% settles Feb 12
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $0.0260 Now $0.0290 +11.54% settles Feb 10
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $0.0400 Now $0.0290 −27.50% settles Feb 5
- Nov 5, 202611d ago 8-K Bearish 8/10 Entry $0.0601 Now $0.0290 +51.75% settles Feb 3
- Nov 2, 202614d ago 8-K Bearish 10/10 Entry $0.0883 Now $0.0290 +67.16% settles Feb 1
- Nov 2, 202614d ago 8-K Bearish 7/10 Entry $0.1120 Now $0.0290 +74.11% settles Jan 29
- Oct 28, 202619d ago SC 13G/A Bearish 5/10 Entry $0.8798 Now $0.0290 +96.70% settles Jan 27
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $0.5175 Now $0.0290 +94.40% settles Jan 21
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $0.3150 Now $0.0290 −90.79% settles Jan 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers